Furthermore, the prognosis of patients with HER2-low and HER2-0 breast cancer, who were treated with HER2 tyrosine kinase inhibitor (TKI), chemotherapy, endocrine therapy or CDK4/6 inhibitors therapy, and the prognostic differences in specific mutation characteristics between the two groups, were thoroughly discussed. The gene discussed is CDK4; the disease is breast carcinoma.